Histocompatibility testing is essential for donor identification and risk assessment in solid organ and hematopoietic stem cell transplant. Additionally, it is useful for identifying donor specific alleles for monitoring donor specific antibodies in post-transplant patients. Next-generation sequence (NGS) based human leukocyte antigen (HLA) typing has improved many aspects of histocompatibility testing in hematopoietic stem cell and solid organ transplant. HLA disease association testing and research has also benefited from the advent of NGS technologies. In this review we discuss the current impact and future applications of NGS typing on clinical histocompatibility testing for transplant and non-transplant purposes.

组织相容性测试对于实体器官和造血干细胞移植中的供体鉴定和风险评估至关重要。此外，它还可用于识别供体特异性等位基因，以监测移植后患者的供体特异性抗体。基于下一代序列 (NGS) 的人类白细胞抗原 (HLA) 分型改善了造血干细胞和实体器官移植中组织相容性测试的许多方面。HLA 疾病关联测试和研究也受益于 NGS 技术的出现。在这篇综述中，我们讨论了 NGS 分型对移植和非移植目的临床组织相容性检测的当前影响和未来应用。